Quince Therapeutics Inc
QNCX1.636USD
-0.044-2.61%
Market hours （ET）Quotes delayed by 15 min
72.14MMarket Cap
LossP/E TTM
More Details of Quince Therapeutics Inc Company
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.
Company Info
Ticker SymbolQNCX
Company nameQuince Therapeutics Inc
IPO dateMay 09, 2019
CEODr. Dirk Thye, M.D.
Number of employees36
Security typeOrdinary Share
Fiscal year-endMay 09
Address601 Gateway Boulevard, Suite 1250
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone14159105717
Websitehttps://quincetx.com/
Ticker SymbolQNCX
IPO dateMay 09, 2019
CEODr. Dirk Thye, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Dirk Thye, M.D.
Dr. Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, Director
Chief Executive Officer, Chief Medical Officer, Director
1.01M
+17.55%
Mr. Brendan Hannah
Mr. Brendan Hannah
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
342.39K
+12.39%
Dr. Charles S. Ryan, Ph.D.
Dr. Charles S. Ryan, Ph.D.
President
President
130.01K
+6.16%
Dr. Luca Benatti, Ph.D.
Dr. Luca Benatti, Ph.D.
Independent Director
Independent Director
80.26K
--
Mr. David A. Lamond, J.D.
Mr. David A. Lamond, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
Mr. Christopher J. Senner, CPA
Mr. Christopher J. Senner, CPA
Independent Director
Independent Director
--
--
Dr. Rajiv Patni, M.D.
Dr. Rajiv Patni, M.D.
Independent Director
Independent Director
--
--
Dr. Una Ryan, OBE
Dr. Una Ryan, OBE
Lead Independent Director
Lead Independent Director
--
--
Dr. Margaret A. Mcloughlin, Ph.D.
Dr. Margaret A. Mcloughlin, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Dirk Thye, M.D.
Dr. Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, Director
Chief Executive Officer, Chief Medical Officer, Director
1.01M
+17.55%
Mr. Brendan Hannah
Mr. Brendan Hannah
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
342.39K
+12.39%
Dr. Charles S. Ryan, Ph.D.
Dr. Charles S. Ryan, Ph.D.
President
President
130.01K
+6.16%
Dr. Luca Benatti, Ph.D.
Dr. Luca Benatti, Ph.D.
Independent Director
Independent Director
80.26K
--
Mr. David A. Lamond, J.D.
Mr. David A. Lamond, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lamond (David A.)
9.64%
Genextra S.p.A.
6.17%
The Vanguard Group, Inc.
2.83%
Sofinnova Partners
2.63%
Thye (Dirk)
2.22%
Other
76.50%
Shareholders
Shareholders
Proportion
Lamond (David A.)
9.64%
Genextra S.p.A.
6.17%
The Vanguard Group, Inc.
2.83%
Sofinnova Partners
2.63%
Thye (Dirk)
2.22%
Other
76.50%
Shareholder Types
Shareholders
Proportion
Individual Investor
13.14%
Venture Capital
9.22%
Investment Advisor
6.89%
Hedge Fund
2.48%
Family Office
1.77%
Investment Advisor/Hedge Fund
1.52%
Research Firm
0.21%
Pension Fund
0.12%
Bank and Trust
0.02%
Other
64.62%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
95
15.28M
33.61%
-3.19M
2025Q1
103
15.28M
33.71%
-3.42M
2024Q4
110
16.30M
37.03%
-3.29M
2024Q3
128
15.88M
36.71%
-1.87M
2024Q2
148
16.69M
38.64%
-2.87M
2024Q1
198
17.67M
40.98%
-3.53M
2023Q4
217
17.25M
42.40%
-4.99M
2023Q3
271
15.70M
40.68%
-12.96M
2023Q2
273
16.49M
45.87%
-11.39M
2023Q1
286
15.20M
42.33%
-10.31M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lamond (David A.)
4.38M
9.64%
--
--
Mar 31, 2025
Genextra S.p.A.
2.81M
6.17%
+280.66K
+11.11%
Oct 18, 2024
The Vanguard Group, Inc.
1.29M
2.83%
+13.43K
+1.06%
Mar 31, 2025
Sofinnova Partners
1.20M
2.63%
-1.20M
-50.05%
Mar 31, 2025
Thye (Dirk)
1.01M
2.22%
+150.94K
+17.55%
Jun 18, 2025
EPIQ Capital Group, LLC
824.78K
1.81%
-1.16K
-0.14%
Dec 31, 2024
IEQ Capital LLC
806.78K
1.77%
+806.78K
--
Mar 31, 2025
Renaissance Technologies LLC
499.91K
1.1%
-23.14K
-4.42%
Mar 31, 2025
Geode Capital Management, L.L.C.
395.71K
0.87%
+19.78K
+5.26%
Mar 31, 2025
Hightower Advisors, LLC
343.57K
0.76%
+2.00K
+0.59%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
